Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.
about
Antibody-based immunotherapy of solid cancers: progress and possibilitiesPhase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.HER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomas.Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical RoleADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancerLJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer.Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.HER3/ErbB3, an emerging cancer therapeutic target.Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyThe prospect of patritumab for treating non-small cell lung cancer.Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.Chaperone proteins as single component reagents to assess antibody nonspecificity.Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide.S-trityl-L-cysteine, a novel Eg5 inhibitor, is a potent chemotherapeutic strategy in neuroblastoma.
P2860
Q26796542-F9D8FB38-2319-4FFE-937C-24EDEC4B709FQ33887412-420C1088-AE3C-4DEE-A9B9-29278C2120E1Q34506951-26D734AF-543C-4668-9AB1-E313A37DF738Q35842236-67775598-1623-4679-A495-EE3E03203E62Q36962935-D14F2176-4306-4A74-93AC-9EEBC5C07D5EQ37375251-218F635F-6102-484F-80C3-353E51F208DAQ37578368-C73EC220-BA80-4ED7-BD5A-BCA1B5EE8023Q37692080-7A103053-3169-4777-830A-DC7C977EE3CDQ38615197-505A82EC-1A7B-43F7-A01D-F01A6466624AQ38867798-A1B322F5-1191-4A72-A392-0307405D7F19Q38876644-1F6885DB-A2AE-48EC-B429-A8FC17F6D007Q38945259-10EDC566-954D-48E9-B666-7775EF81FB9DQ38981780-21491AEB-AEB6-4FA6-AF09-7BE50034F5B3Q39886940-6A7A679A-E761-4D92-82AF-96F150B56533Q42280823-58FC611E-7D76-4A9C-84E5-CFFFD68F3F30Q50876579-510F63C6-DACB-4B75-8576-A91711F6753AQ55410033-E71BC427-B2DE-4800-874F-659110C64C31
P2860
Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phase 1 and dose-finding study ...... ts with advanced solid tumors.
@ast
Phase 1 and dose-finding study ...... ts with advanced solid tumors.
@en
type
label
Phase 1 and dose-finding study ...... ts with advanced solid tumors.
@ast
Phase 1 and dose-finding study ...... ts with advanced solid tumors.
@en
prefLabel
Phase 1 and dose-finding study ...... ts with advanced solid tumors.
@ast
Phase 1 and dose-finding study ...... ts with advanced solid tumors.
@en
P2093
P2860
P1476
Phase 1 and dose-finding study ...... ts with advanced solid tumors.
@en
P2093
Hiroshi Nokihara
Hiroshi Wakui
Noboru Yamamoto
Shinji Nakamichi
Tomohide Tamura
Yasuhide Yamada
Yousuke Tamura
P2860
P2888
P304
P356
10.1007/S00280-014-2375-2
P577
2014-01-18T00:00:00Z
P5875
P6179
1048911857